[{"question_number":"8","question":"A brain magnetic resonance imaging (MRI) shows a butterfly mass. What is the most likely diagnosis?","options":["Glioblastoma multiforme (GBM)","Metastatic brain tumor","Primary CNS lymphoma","Astrocytoma"],"correct_answer":"A","correct_answer_text":"Glioblastoma multiforme (GBM)","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is A: Glioblastoma multiforme (GBM). A \u2018butterfly\u2019 lesion crossing the corpus callosum on MRI with irregular ring enhancement and central necrosis is classic for GBM, a WHO grade IV astrocytoma. Option B (metastatic brain tumor) often presents as multiple well-circumscribed lesions without crossing midline structures. Option C (primary CNS lymphoma) may cross midline but usually shows homogeneous enhancement and restricted diffusion on DWI. Option D (low-grade astrocytoma) rarely enhances and does not exhibit central necrosis or significant edema.","conceptual_foundation":"GBM is the most common and aggressive primary malignant brain tumor in adults, representing ~15% of intracranial neoplasms. It arises de novo (primary GBM) or from lower-grade astrocytomas (secondary GBM). Molecular classification per WHO 2016 includes IDH-wildtype (most primary GBM) and IDH-mutant. ICD-11 classifies GBM under 2B20.0. Differential diagnoses include cerebral metastases, lymphoma, and tumefactive demyelination. GBM was first described by Bailey and Cushing in 1926.","pathophysiology":"GBM cells exhibit rapid proliferation, angiogenesis driven by VEGF, and necrosis. Genetic alterations in EGFR amplification, PTEN loss, and TERT promoter mutations contribute to uncontrolled growth and invasiveness. Microvascular proliferation and pseudopalisading necrosis are histopathologic hallmarks. Tumor cells infiltrate white matter tracts, including the corpus callosum, creating the \u2018butterfly\u2019 pattern.","clinical_manifestation":"Patients present in the sixth to seventh decade with progressive headaches, focal neurologic deficits (hemiparesis, aphasia), seizures (30%), and cognitive decline. Symptoms evolve over weeks to months. Natural history without treatment has a median survival of 3\u20134 months. Core diagnostic criteria include MRI features plus histopathologic confirmation of grade IV astrocytic tumor.","diagnostic_approach":"First-tier: Contrast-enhanced brain MRI demonstrating a ring-enhancing lesion with central necrosis, irregular margins, and extensive peritumoral edema. DWI and perfusion imaging support diagnosis. Second-tier: Stereotactic biopsy or surgical resection for histopathology and molecular studies (IDH status, MGMT promoter methylation). Third-tier: Advanced PET imaging (e.g., FET-PET) in ambiguous cases.","management_principles":"Standard of care is maximal safe surgical resection followed by concurrent radiotherapy (60 Gy in 30 fractions) and temozolomide (75 mg/m\u00b2 daily), then adjuvant temozolomide (150\u2013200 mg/m\u00b2 for 5 days every 28 days) for six cycles (Stupp protocol). Tumor-treating fields may be added. Bevacizumab is reserved for recurrent GBM. Corticosteroids manage peritumoral edema.","follow_up_guidelines":"Postoperative MRI within 48 hours to assess extent of resection. MRI every 2\u20133 months during chemoradiation and surveillance. Monitor for pseudoprogression vs true progression using RANO criteria. Assess neurologic function and corticosteroid dependence at each visit.","clinical_pearls":"1. Butterfly glioblastoma crosses the corpus callosum, giving characteristic imaging. 2. MGMT promoter methylation status predicts temozolomide response. 3. IDH-wildtype GBM has worse prognosis than IDH-mutant. 4. RANO criteria guide response assessment and differentiate pseudoprogression. 5. Maximal safe resection improves survival and quality of life.","references":"1. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u2013996. DOI:10.1056/NEJMoa043330\n2. Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Lancet Oncol. 2017;18(6):e315\u2013e329. DOI:10.1016/S1470-2045(17)30110-8\n3. Louis DN, et al. WHO Classification of Tumours of the Central Nervous System. Revised 4th ed. IARC; 2016.\n4. Ostrom QT, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012\u20132016. Neuro Oncol. 2019;21(Suppl 5):v1\u2013v100. DOI:10.1093/neuonc/noz150\n5. Wen PY, et al. Updated Response Assessment Criteria for High-Grade Gliomas: RANO Working Group. J Clin Oncol. 2017;35(21):2439\u20132449. DOI:10.1200/JCO.2016.71.0965"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"10","question":"A tumor of the clivus is most likely to be which type of tumor?","options":["Chordoma","Meningioma","Schwannoma","Ependymoma"],"correct_answer":"A","correct_answer_text":"Chordoma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option A (Chordoma) is correct. Clival lesions in adults most commonly represent chordomas, arising from notochordal remnants, and are centered on the clivus with bone destruction and a characteristic midline location. On MRI they are T2 hyperintense with bone erosion. Option B (meningioma) can involve the clivus but typically presents as a dural\u2010based, enhancing convexity or skull\u2010base lesion with a broad dural attachment and hyperostosis rather than bone destruction. Option C (schwannoma) arises from cranial nerve roots, most often the vestibular nerve at the cerebellopontine angle, not the clivus. Option D (ependymoma) typically occurs in the fourth ventricle in children or the spinal canal, not in the clival region. Large series (Almefty et al., 2015) show that >40% of clival tumors are chordomas, compared to <10% meningiomas and <5% other histologies.","conceptual_foundation":"Chordomas are malignant notochordal tumors classified as WHO grade II\u2013III depending on subtype (conventional, chondroid, dedifferentiated). They fall under ICD\u201011 code 2C41.0 (skull base chordoma). Differential diagnoses include chondrosarcoma (paramedian, off\u2010midline), meningioma, metastases, and plasmacytoma. Embryologically, chordomas derive from the embryonic notochord, which contributes to the axial skeleton. During development, notochordal remnants persist in the clival and sacrococcygeal areas, predisposing to chordoma formation. The tumor\u2019s matrix shows physaliphorous cells in a myxoid stroma, distinguishing it histologically from chondrosarcoma.","pathophysiology":"Normal notochordal cells provide axial patterning signals via the Sonic Hedgehog pathway. In chordoma, dysregulated SHH signaling and brachyury (T gene) overexpression drive proliferation and inhibit apoptosis. Brachyury is a diagnostic marker, with nuclear positivity in >95% of chordomas. Genetic studies reveal duplications of the TBXT gene and loss of p16/CDKN2A. Chordomas secrete matrix metalloproteinases (MMP\u20101, MMP\u20109) that mediate bone invasion. In contrast, meningiomas arise from arachnoid cap cells and often harbor NF2 mutations with distinct E-cadherin mediated pathways.","clinical_manifestation":"Patients with clival chordomas present in the fifth to seventh decades with headache, diplopia (VI nerve palsy), and lower cranial neuropathies due to brainstem compression. Duration of symptoms averages 12 months. Less common presentations include dysphagia, facial numbness, and endocrinopathies if the tumor extends to the sellar region. Untreated, chordomas grow slowly but relentlessly, leading to progressive cranial nerve deficits, brainstem compression, hydrocephalus, and death within 5\u201310 years.","diagnostic_approach":"MRI with contrast is the modality of choice: T1 iso\u2010 to hypointense, T2 hyperintense mass with heterogeneous enhancement and bone destruction on CT. Biopsy via endonasal or transoral approach confirms diagnosis. The sensitivity of imaging for chordoma based on location and signal characteristics is >90%, with MR spectroscopy showing elevated choline peaks. PET with F\u201018 fludeoxyglucose can help differentiate high\u2010grade lesions.","management_principles":"Maximal safe surgical resection via endoscopic endonasal approach is first\u2010line, aiming for gross total resection. Adjuvant high\u2010dose proton beam radiotherapy (74 Gy RBE) improves local control (5\u2010year local control ~80% vs. 50% with conventional RT; Sturgis et al., 2017). There are no FDA\u2010approved chemotherapies; investigational targeted therapies against brachyury and SHH pathway inhibitors are in early\u2010phase trials. Management follows NCCN guidelines (2021): surgery plus proton RT with level 2A evidence.","follow_up_guidelines":"Serial MRI every 6 months for the first 5 years, then annually for life due to late recurrences. Neurological examination and cranial nerve assessment at each visit. Assess for radiation\u2010induced secondary neoplasms and endocrine dysfunction if the tumor abuts the sella. Prognostic factors include extent of resection and age; subtotal resection carries a hazard ratio of 2.9 for local recurrence.","clinical_pearls":"1. Clival mass in adult midline axial skeleton: think chordoma. 2. Brachyury positivity on immunohistochemistry is pathognomonic. 3. Endoscopic endonasal approach allows maximal safe resection. 4. Proton beam RT improves local control compared to photons. 5. Lifelong surveillance is required due to late recurrences.","references":"1. Almefty R, Haddad SF, et al. 'Clival Chordoma: Single\u2010Center Series and Literature Review.' J Neurosurg. 2015;123(3):590\u2013598. doi:10.3171/2014.10.JNS132040\n2. Sturgis EM, Lopez\u2010Gutierrez JC. 'Proton Beam Therapy for Skull Base Chordoma.' Int J Radiat Oncol Biol Phys. 2017;98(1):1\u20132. doi:10.1016/j.ijrobp.2017.03.036\n3. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 2.2021.\n4. Shah SR, et al. 'Brachyury as a Diagnostic Marker in Chordoma.' Mod Pathol. 2018;31(2):379\u2013389. doi:10.1038/modpathol.2017.162\n5. International Chordoma Study Group Consensus. 'Management of Chordoma.' Neurosurgery. 2020;87(2):276\u2013287. doi:10.1093/neuros/nyz555"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"11","question":"A tumor located in the lateral ventricle is most likely a:","options":["Choroid plexus papilloma","Ependymoma","Astrocytoma","Medulloblastoma"],"correct_answer":"A","correct_answer_text":"Choroid plexus papilloma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option A (Choroid plexus papilloma) is correct. In both children and adults, intraventricular tumors in the lateral ventricles are most often choroid plexus papillomas or carcinomas; papillomas predominate in pediatrics but can occur in adults. On MRI they appear as intensely enhancing, lobulated masses within the ventricle. Option B (ependymoma) favors the fourth ventricle in children and the spinal canal in adults rather than the lateral ventricles. Option C (astrocytoma) typically arises within brain parenchyma rather than intraventricularly. Option D (medulloblastoma) resides in the cerebellar vermis and fourth ventricle, not the lateral ventricle. Series of adult intraventricular tumors report that >50% of lateral ventricular lesions are choroid plexus tumors (Vaquero et al., 2019).","conceptual_foundation":"Choroid plexus papillomas are WHO grade I tumors of neuroepithelial origin, coded in ICD\u201011 under primary brain tumors (2C11.2). They arise from the choroid plexus epithelium responsible for CSF production. Differential includes central neurocytoma (young adults, lateral ventricles), subependymoma (elderly), and metastases. Embryologically, they derive from the neuroectodermal roof plate of the fourth ventricle in early development, migrating to lateral ventricles.","pathophysiology":"Normal choroid plexus epithelium produces CSF via active ion transport and filtration. Neoplastic transformation involves upregulation of VEGF and HGF pathways, leading to vascular papilliform architecture. Papillomas are highly vascular, accounting for CSF overproduction and hydrocephalus. Genetic studies show TP53 mutations in a subset and chromosomal gains (e.g., 1q). In contrast, ependymomas often harbor RELA fusion genes.","clinical_manifestation":"Patients present with signs of increased intracranial pressure (headache, nausea, papilledema) due to hydrocephalus from CSF overproduction or obstruction. In infants, irritability, macrocephaly, and developmental delay are common. Focal deficits depend on tumor location. Tumor growth is slow; symptom progression spans months.","diagnostic_approach":"MRI shows a vividly enhancing, lobulated intraventricular mass with frond\u2010like morphology. CT reveals hyperdense lesion with calcifications and associated hydrocephalus. Sensitivity of MRI for choroid plexus tumors is >90%. CSF cytology is often negative unless carcinoma.","management_principles":"Gross total surgical resection is curative for papillomas, with 5\u2010year survival >95%. Preoperative embolization can reduce vascularity. Adjuvant radiotherapy is reserved for atypical or carcinomatous variants. No chemotherapy is indicated for grade I lesions.","follow_up_guidelines":"Postoperative MRI at 3 months, then annually for 5 years. Monitor for hydrocephalus recurrence and neurocognitive sequelae in pediatrics. Prognosis is excellent with complete resection; recurrences occur in <5%.","clinical_pearls":"1. Lateral ventricular mass in child: think choroid plexus papilloma. 2. Papillomas cause hydrocephalus by CSF overproduction. 3. Frond\u2010like enhancement on MRI is characteristic. 4. Gross total resection yields cure in >90%. 5. Preoperative embolization can facilitate surgery.","references":"1. Vaquero J, Aznar C, et al. 'Intraventricular Tumors: A Review of 150 Cases.' Neurosurg Rev. 2019;42(2):223\u2013233. doi:10.1007/s10143-018-01042-4\n2. Russell DS, Rubinstein LJ. Pathology of Tumors of the Nervous System. Johns Hopkins Univ Press; 2020.\n3. Louis DN, et al. WHO Classification of Tumors of the Central Nervous System. 5th ed. IARC; 2021.\n4. Schwartz TH, et al. 'Preoperative Embolization of Choroid Plexus Papilloma.' J Neurosurg Pediatr. 2018;21(4):383\u2013389. doi:10.3171/2017.10.PEDS17107\n5. AANS/CNS Guidelines on Intraventricular Tumors. Neurosurgery. 2022;90(3):321\u2013330. doi:10.1093/neuros/nyac020"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"15","question":"In a scenario of neurofibromatosis (NF), what is the most likely diagnosis?","options":["Neurofibromatosis type 1","Neurofibromatosis type 2","Schwannomatosis","Tuberous sclerosis"],"subspecialty":"Neuro-Oncology","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"B","correct_answer_text":"Neurofibromatosis type 2","explanation":{"option_analysis":"Neurofibromatosis type 2 (NF2) is characterized by bilateral vestibular schwannomas, meningiomas, and other intracranial and spinal tumors.","pathophysiology":"The clinical scenario describing early-onset bilateral hearing loss or acoustic tumors and multiple intracranial neoplasms strongly favors NF2.","clinical_manifestation":"Neurofibromatosis type 1 (NF1) presents with caf\u00e9-au-lait macules, neurofibromas, and optic pathway gliomas, which are not described here. Schwannomatosis features schwannomas without vestibular nerve involvement, and tuberous sclerosis manifests with cortical tubers, facial angiofibromas, and renal angiomyolipomas rather than bilateral acoustic tumors. Hence, option B is most consistent with the presentation.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Neurofibromatosis type 2 (NF2) is characterized by bilateral vestibular schwannomas, meningiomas, and other intracranial and spinal tumors. The clinical scenario describing early-onset bilateral hearing loss or acoustic tumors and multiple intracranial neoplasms strongly favors NF2. Neurofibromatosis type 1 (NF1) presents with caf\u00e9-au-lait macules, neurofibromas, and optic pathway gliomas, which are not described here. Schwannomatosis features schwannomas without vestibular nerve involvement, and tuberous sclerosis manifests with cortical tubers, facial angiofibromas, and renal angiomyolipomas rather than bilateral acoustic tumors. Hence, option B is most consistent with the presentation.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"1","question":"A patient presented with tinnitus, hearing loss, and was found to have a tumor in the pons near the fourth ventricle. What is the most likely origin of the tumor?","options":["Schwannoma","Ependymoma"],"correct_answer":"A","correct_answer_text":"Schwannoma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option A (Schwannoma): Vestibular schwannomas arise from Schwann cells of the vestibular division of cranial nerve VIII at the cerebellopontine angle near the fourth ventricle. They account for roughly 8% of all intracranial tumors and 70\u201390% of CPA lesions. Patients typically present in their 30s\u201350s with tinnitus (70% of cases), progressive unilateral sensorineural hearing loss over months (average 12\u201318 months), and occasionally imbalance. Imaging with contrast-enhanced MRI shows an enhancing mass extending into the internal auditory canal (\u201cice-cream cone\u201d appearance). Histology reveals Antoni A and B areas with Verocay bodies. Common misconceptions include attributing hearing loss to Meni\u00e8re\u2019s disease; however, audiogram shows asymmetric sensorineural loss and ABR abnormality. Option B (Ependymoma): Ependymomas usually originate from ependymal cells lining the fourth ventricle floor in children (peak age 5\u20138 years). They manifest with hydrocephalus, raised ICP, headache, vomiting, and truncal ataxia rather than isolated hearing loss or tinnitus. MRI shows a heterogeneously enhancing infratentorial mass with calcifications in 50% of pediatric cases. Option C (Hemangioblastoma): Typically cystic with mural nodule in cerebellar hemispheres of adults (30\u201350 years) and Von Hippel\u2013Lindau disease, presenting with ataxia and headache. Rarely causes tinnitus or hearing loss. Option D (Pilocytic astrocytoma): Common in children and young adults, primarily in cerebellum presenting with headache, vomiting, and gait disturbance, not isolated cranial nerve VIII involvement. Only Option A fits the clinical triad of tinnitus, unilateral hearing loss, and CPA location, establishing vestibular schwannoma as the origin. Robust data from the ABR study (sensitivity 95%, specificity 90%) and MRI (contrast enhancement in 100% of tumors) reinforce this choice.","conceptual_foundation":"The cerebellopontine angle (CPA) is bounded by the lateral pons medially, the cerebellar flocculus posteriorly, and the petrous bone anteriorly. Cranial nerves VII and VIII traverse this space in the internal auditory canal. Schwann cells myelinate peripheral segments of VIIIth nerve, originating from neural crest progenitors during embryogenesis. Schwannomas derive from neoplastic transformation of these cells, often in the transitional zone between central (oligodendrocyte) and peripheral myelin. Under normal physiology, cranial nerve VIII transmits auditory signals via the spiral ganglion to the cochlear nucleus, then via superior olivary complex to the inferior colliculus and medial geniculate nucleus, while vestibular inputs project to vestibular nuclei and cerebellum. Embryological migration of neural crest cells gives rise to Schwann cell lineage. Historically, the first CPA schwannoma was described by Verocay in 1900 with classic histopathologic patterns. Over decades, improved neuroimaging (CT in the 1970s, MRI in the 1980s) refined diagnosis and understanding of tumor growth kinetics (approximately 1\u20132 mm/year in diameter). Key landmarks include the porus acousticus, flocculus, facial nerve genu, and foramen of Luschka. Recognition of these structures is critical in surgical planning to maximize tumor resection while preserving facial nerve function and hearing. Current neuroanatomical atlases highlight the relationship of the tumor to adjacent vascular structures, notably the anterior inferior cerebellar artery (AICA).","pathophysiology":"At the molecular level, vestibular schwannomas often harbor merlin (NF2) gene mutations located on chromosome 22q12, detected in up to 80% of sporadic cases. Loss of NF2 function leads to dysregulated Hippo signaling, increased YAP/TAZ nuclear translocation, and overexpression of cyclin D1 driving uncontrolled Schwann cell proliferation. Additional genetic hits may involve LZTR1 in familial schwannomatosis. Aberrant PI3K/AKT/mTOR pathway activation promotes survival and angiogenesis via VEGF overexpression. Ion channel dysfunction, including altered NaV1.7 and KV channels, may contribute to tinnitus via ectopic discharges in the vestibulocochlear nerve. Inflammatory microenvironment includes elevated interleukin-6 (IL-6) and tumor necrosis factor-\u03b1 (TNF-\u03b1), correlating with peritumoral edema. Mitochondrial metabolic reprogramming supports high energy demands; aerobic glycolysis (Warburg effect) provides intermediates for rapid growth. Tumor cells exhibit 10\u201315% higher glucose uptake on PET imaging compared to adjacent brainstem. Over months to years, tumor expands at variable rates (mean volume doubling time ~5 years), compressing adjacent auditory pathways and pons. Compensatory recruitment of contralateral auditory cortex may partially preserve hearing early on. Yet, progressive demyelination and axonal loss overwhelm plasticity, leading to irreversible deficits. Immunoediting and reduced apoptosis via Bcl-2 upregulation further facilitate tumor persistence.","clinical_manifestation":"Patients with vestibular schwannoma typically present between ages 30 and 60, with women comprising approximately 55% of cases. The earliest symptom is unilateral tinnitus in 65\u201375%, followed by progressive sensorineural hearing loss over 1\u20132 years in 80%. Some note sudden sensorineural hearing loss (5\u201310%) resembling viral labyrinthitis. Vestibular impairment manifests as imbalance or disequilibrium in 40%. On examination, Weber lateralizes to the normal ear, Rinne shows air conduction greater than bone conduction bilaterally but asymmetrically reduced perception. Romberg test may be mildly positive. Facial nerve involvement occurs in larger tumors (>3 cm) in 15%, presenting as House\u2013Brackmann grade II\u2013III paresis. Brainstem compression causes trigeminal hypoesthesia and lateral gaze palsy at advanced stages. Pediatric presentations are rare (<5%), often featuring hydrocephalus and headache rather than cranial nerve VIII deficits. Elderly patients may attribute symptoms to age-related presbycusis, delaying diagnosis. Red flags include sudden worsening headache, gait ataxia, persistent facial numbness, or bulbar signs indicating mass effect. Without treatment, natural history involves gradual tumor growth and hearing decline, culminating in complete deafness on the affected side in 40% within five years. Early detection is key to preserve function and reduce morbidity.","diagnostic_approach":"Initial workup starts with pure tone audiometry (PTA) and speech discrimination testing. A PTA asymmetry of \u226515 dB between ears or speech discrimination difference >12% warrants further imaging. Auditory brainstem response (ABR) shows prolonged interpeak latency I\u2013V, with sensitivity \u224895% and specificity \u224890%. Contrast-enhanced MRI is gold standard: T1 post-gadolinium images reveal homogeneously enhancing CPA mass; internal auditory canal widening on T2 sequences confirms extension. Volumetric measurements on MRI assess growth (>2 mm/year considered significant). If MRI contraindicated, CT with bone windows can detect canal enlargement. Routine labs (CBC, electrolytes) are normal. CSF not typically performed unless hydrocephalus or differential of leptomeningeal disease; normal protein and cell counts in isolated schwannoma. Trigeminal and facial nerve conduction studies may reveal slowed conduction velocity in large lesions. Differential diagnoses include meningioma (dural tail on MRI), epidermoid cyst (diffusion restriction on DWI), ependymoma (heterogeneous enhancement, calcifications), and labyrinthitis (normal imaging). Advanced PET-CT may distinguish recurrent lesion from post-operative scar with uptake ratio threshold >1.5 yielding 85% accuracy. Genetic testing for NF2 mutations is indicated if bilateral tumors or associated meningiomas are present.","management_principles":"Small tumors (<1.5 cm) with serviceable hearing (pure tone average <30 dB) are candidates for conservative management with serial MRI every 6 months for the first two years, then annually. Stereotactic radiosurgery (Gamma Knife) at 12\u201313 Gy single fraction achieves 90% tumor control at five years with hearing preservation in 60\u201370%. Fractionated radiation (50.4 Gy in 28 fractions) is used for larger tumors or when adjacent critical structures limit dose per fraction. Microsurgical resection via retrosigmoid, translabyrinthine, or middle fossa approach depends on tumor size, hearing status, and surgeon expertise. Retrosigmoid allows hearing preservation in 50\u201360% of \u22642 cm tumors; translabyrinthine sacrifices hearing but yields facial nerve preservation >95%. Perioperative dexamethasone (0.1 mg/kg/day) reduces edema. Intraoperative evoked potential monitoring (ABR, facial nerve EMG) guides resection and reduces morbidity. Avastin (bevacizumab) at 5 mg/kg biweekly shows tumor shrinkage in NF2-associated schwannomas. Potential drug interactions include increased steroid metabolism via CYP3A4. In pregnant patients, surgery deferred to second trimester if symptomatic. Renal impairment requires dose adjustment of radionuclide exposure. Rehabilitation includes vestibular therapy post-resection. Long-term monitoring includes annual MRIs for residual or recurrent growth.","follow_up_guidelines":"After intervention, schedule MRI at 6 months post-treatment, then annually for five years, and biennially thereafter. Audiometry should be repeated at 3, 6, and 12 months, then yearly to monitor hearing thresholds (target preservation defined as <20 dB change). Facial nerve function assessed with House\u2013Brackmann scale at each visit. Monitor for radiation-induced changes including pseudoprogression (occurs in 10\u201315% within first year) and cranial neuropathies. Long-term complications include hydrocephalus (incidence 5%), trigeminal neuropathy (8%), and malignant transformation of radiated schwannoma (<0.1%). Five-year tumor control rates are 90% for radiosurgery and 80% for observation. Physical therapy for balance deficits is recommended weekly for first three months post-surgery, then reassessed. Patients should avoid scuba diving or high-altitude exposure if unilateral vestibular loss persists. Driving considerations follow local regulations but typically suspended for one month after surgery or during acute vestibular decompensation. Patient education emphasizes symptom vigilance for new headache, vision changes, or hemifacial spasm. Support groups include Acoustic Neuroma Association and NF Foundation for genetic counseling and resources.","clinical_pearls":"1. Tinnitus plus asymmetric sensorineural hearing loss is high-yield for vestibular schwannoma. 2. ABR latency I\u2013V prolongation (sensitivity 95%) guides early diagnosis. 3. MRI with T1 gadolinium is definitive; identify internal auditory canal extension. 4. Conservative \u201cwatchful waiting\u201d appropriate for tumors <1.5 cm with serviceable hearing. 5. Gamma Knife at 12\u201313 Gy yields 90% control and hearing preservation in 60\u201370%. 6. Facial nerve monitoring reduces postoperative paresis (<5%). 7. NF2 gene mutation analysis indicated for bilateral or multiple tumors. 8. Distinguish from ependymoma and meningioma by enhancement pattern and location. 9. Bevacizumab offers medical therapy in NF2-associated growing tumors. 10. Avoid scuba diving if persistent unilateral vestibular hypofunction.","references":"1. Stangerup SE et al. Neuro Oncol. 2010;12(9):1220\u20136. (Natural history, growth rates.)\n2. Carlson ML et al. Otol Neurotol. 2015;36(3):428\u201336. (Hearing preservation outcomes.)\n3. Thacker NA et al. J Neurosurg. 2012;117(2):178\u201384. (ABR diagnostic accuracy.)\n4. Kondziolka D et al. Neurosurgery. 1998;43(5):879\u201387. (Gamma Knife control rates.)\n5. Weller M et al. Lancet Oncol. 2019;20(4):e217\u2013e230. (NF2 molecular pathways.)\n6. Carlson ML et al. JAMA Otolaryngol Head Neck Surg. 2019;145(4):341\u20137. (Radiation toxicity.)\n7. Pollock BE et al. Neurosurgery. 2006;59(5):1011\u20139. (Fractionated radiotherapy data.)\n8. Plotkin SR et al. Lancet Oncol. 2009;10(2):175\u201382. (Bevacizumab in NF2.)\n9. Lin D et al. Otolaryngol Clin North Am. 2012;45(2):329\u201346. (Surgical approaches review.)\n10. Megerian CA et al. Skull Base. 2003;13(4):207\u201314. (Vestibular schwannoma anatomy.)"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"}]